Background: There is increasing evidence that altered immune responses play a role in the pathogenesis of autism spectrum disorders (ASD), together with dysfunction of the serotonergic and glutamatergic systems. Since the kynurenine (KYN) pathway that degrades tryptophan (TRP) is activated in various neuroinflammatory states, we aimed to determine whether this pathway is activated in ASD. Methods: Sixty-five pediatric ASD patients (including 52 boys) were enrolled from an epidemiological survey covering 2 counties in Norway; 30 (46.5%) of these patients were diagnosed with childhood autism, 16 (24.6%) with Asperger syndrome, 12 (18.5%) with atypical autism, 1 (1.5%) with Rett syndrome, and 6 (9.2%) with other ASD. The serum levels of the following markers were measured in the children with ASD and compared to those in 30 healthy children: TRP, KYN, kynurenic acid (KA), 3-hydroxykynurenine, and quinolinic acid. Results: The mean serum level of KA was significantly lower in the ASD group than in the healthy controls (28.97 vs. 34.44 nM, p = 0.040), while the KYN/KA ratio was significantly higher in the ASD group (61.12 vs. 50.39, p = 0.006). The same relative values were found when comparing the childhood autism subgroup with the controls. Also, the mean serum level of TRP was significantly lower in children with a subdiagnosis of childhood autism than in those with Asperger syndrome (67.26 vs. 77.79 μM, p = 0.020). Conclusion: Our study indicates that there is an increased neurotoxic potential and also a possible lower KYN aminotransferase activity in ASD.

Keywords:
Autism spectrum disorders, Kynurenine pathway, Kynurenic acid, Tryptophan
1.
Persico AM, Bourgeron T: Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006; 29: 349–358.
2.
Baird G, et al: Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006; 368: 210–215.
3.
Fombonne E: Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65: 591–598.
4.
Isaksen J, et al: Observed prevalence of autism spectrum disorders in two Norwegian counties. Eur J Paediatr Neurol 2012; 16: 592–598.
5.
Levy SE, Mandell DS, Schultz RT: Autism. Lancet 2009; 374: 1627–1638.
6.
Rogers SJ: Developmental regression in autism spectrum disorders. Ment Retard Dev Disabil Res Rev 2004; 10: 139–143.
7.
Spence SJ, Schneider MT: The role of epilepsy and epileptiform EEGs in autism spectrum disorders. Pediatr Res 2009; 65: 599–606.
8.
Mead J, Ashwood P: Evidence supporting an altered immune response in ASD. Immunol Lett 2015; 163: 49–55.
9.
Gesundheit B, et al: Immunological and autoimmune considerations of autism spectrum disorders. J Autoimmun 2013; 44: 1–7.
10.
Bryn V, et al: Cytokine profile in autism spectrum disorders in children. J Mol Neurosci 2017; 61: 1–7.
11.
Croonenberghs J, et al: Activation of the inflammatory response system in autism. Neuropsychobiology 2002; 45: 1–6.
12.
Masi A, Quintana DS: Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry 2015; 20: 440–446.
13.
Bjorklund G, et al: Immune dysfunction and neuroinflammation in autism spectrum disorder. Acta Neurobiol Exp (Wars) 2016; 76: 257–268.
14.
Gabriele S, Sacco R, Persico AM: Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014; 24: 919–929.
15.
Croonenberghs J, et al: Central serotonergic hypofunction in autism: results of the 5-hydroxy-tryptophan challenge test. Neuro Endocrinol Lett 2007; 28: 449–455.
16.
Croonenberghs J, et al: Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls. Life Sci 2005; 76: 2171–2183.
17.
Schwarcz R, et al: Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465–477.
18.
Bender DA, McCreanor GM: Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 1985; 13: 441–443.
19.
Oxenkrug GF: Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann NY Acad Sci 2007; 1122: 35–49.
20.
Barreto FS, et al: Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer. Behav Pharmacol. 2018; 29: 165–180.
21.
Kita T, et al: Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. J Neurochem 2002; 82: 258–268.
22.
Schwarcz R, et al: Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465–477.
23.
Maes M, Rief W: Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196: 243–249.
24.
Wichers MC, et al: IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.
25.
Maes, M., et al.: The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 702–721.
26.
Alberati-Giani D, Cesura AM: Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino Acids 1998; 14: 251–255.
27.
Okuda S, et al: 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998; 70: 299–307.
28.
Stone TW, Perkins MN: Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981; 72: 411–412.
29.
Swartz KJ, et al: Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990; 10: 2965–2973.
30.
Hilmas C, et al: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001; 21: 7463–7473.
31.
Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309–379.
32.
Fukui S, et al: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991; 56: 2007–2017.
33.
Lapin IP, et al: Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. J Psychopharmacol 1996; 10: 246–249.
34.
Isaksen J, et al: Children with autism spectrum disorders – the importance of medical investigations. Eur J Paediatr Neurol 2013; 17: 68–76.
35.
Herve C, et al: Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl 1996; 675: 157–161.
36.
Erhardt S, et al: Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013; 38: 743–752.
37.
Steiner J, et al: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011; 8: 94.
38.
Sublette ME, et al: Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011; 25: 1272–1278.
39.
Zavitsanou K, et al: Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition. Brain Behav Immun 2014; 41: 173–181.
40.
Lim CK, et al: Altered kynurenine pathway metabolism in autism: implication for immune-induced glutamatergic activity. Autism Res 2016; 9: 621–631.
41.
Beninger RJ, et al: Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 1994; 61: 603–612.
42.
Heyes MP, et al: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115: 1249–1273.
43.
Heyes MP, et al: Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 1992; 40: 71–80.
44.
Anand R, Amici SA, Ponath G, Robson JI, Nasir M, McKay SB: Nicotinic acetylcholine receptor alterations in autism spectrum disorders: biomarkers and therapeutic targets; in Eapen V (ed): Autism: A Neurodevelopmental Journey from Genes to Behaviour. London, InTech, 2011.
45.
Hartai Z, et al: Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci 2005; 239: 31–35.
46.
Hartai Z, et al: Decreased serum and red blood cell kynurenic acid levels in Alzheimer’s disease. Neurochem Int 2007; 50: 308–313.
47.
McDougle CJ, et al: Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 993–1000.
48.
Anderson G, Maes M: Redox regulation and the autistic spectrum: role of tryptophan catabolites, immuno-inflammation, autoimmunity and the amygdala. Curr Neuropharmacol 2014; 12: 148–167.
49.
Gal EM, Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980; 5: 223–239.
50.
Heyes MP, et al: Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996; 320: 595–597.
51.
Curzon G: Relationships between plasma, CSF and brain tryptophan. J Neural Transm Suppl 1979; 81–92.
52.
Raison CL, et al: CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15: 393–403.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.